[
  {
    "ts": "2026-02-09T09:13:34+00:00",
    "headline": "Novo Nordisk shares rise as Hims abandons $49 weight-loss pill",
    "summary": "COPENHAGEN, Feb 9 () - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of ​a $49 weight-loss pill over the weekend, following legal threats from ‌Novo and the U. Hims introduced the compounded pill based on semaglutide - ‌a key ingredient in Novo's blockbuster drugs Wegovy and Ozempic - last Thursday, prompting pushback from the Danish drugmaker and regulatory authorities.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "eba1a6c5-1069-3b02-9249-bb65961b531a",
      "content": {
        "id": "eba1a6c5-1069-3b02-9249-bb65961b531a",
        "contentType": "STORY",
        "title": "Novo Nordisk shares rise as Hims abandons $49 weight-loss pill",
        "description": "",
        "summary": "COPENHAGEN, Feb 9 () - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of ​a $49 weight-loss pill over the weekend, following legal threats from ‌Novo and the U. Hims introduced the compounded pill based on semaglutide - ‌a key ingredient in Novo's blockbuster drugs Wegovy and Ozempic - last Thursday, prompting pushback from the Danish drugmaker and regulatory authorities.",
        "pubDate": "2026-02-09T09:13:34Z",
        "displayTime": "2026-02-09T09:13:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/169cee0bf3615c357bb727c349a37c1f",
          "originalWidth": 800,
          "originalHeight": 527,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q5tu47T4jLBH.vaRgG7MVg--~B/aD01Mjc7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/169cee0bf3615c357bb727c349a37c1f.cf.webp",
              "width": 800,
              "height": 527,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jfLTpFgNiIdojq6eRefROQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/169cee0bf3615c357bb727c349a37c1f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T05:57:00+00:00",
    "headline": "Innovent Biologics Strikes Partnership Deal With Eli Lilly",
    "summary": "Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.",
    "url": "https://www.wsj.com/tech/biotech/innovent-biologics-strikes-partnership-deal-with-eli-lilly-fa6713f9?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "ac224973-802c-35d2-b975-9398f85a9adb",
      "content": {
        "id": "ac224973-802c-35d2-b975-9398f85a9adb",
        "contentType": "STORY",
        "title": "Innovent Biologics Strikes Partnership Deal With Eli Lilly",
        "description": "",
        "summary": "Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.",
        "pubDate": "2026-02-09T05:57:00Z",
        "displayTime": "2026-02-09T05:57:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ac224973-802c-35d2-b975-9398f85a9adb/innovent-biologics-strikes.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6914d8a6fb87a081fde515b59bae8642",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LXMe.ymKL_eN79CDkj2a9w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6914d8a6fb87a081fde515b59bae8642.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ciE_MH1eMDoSTjrzHtPh1w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6914d8a6fb87a081fde515b59bae8642.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/tech/biotech/innovent-biologics-strikes-partnership-deal-with-eli-lilly-fa6713f9?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IVBIY"
            },
            {
              "symbol": "IVBXF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T11:36:51+00:00",
    "headline": "Hims & Hers Halts Knockoff Wegovy Pill After Just Two Days: Here's Why",
    "summary": "Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill.",
    "url": "https://www.investors.com/news/technology/hims-hers-health-stops-offering-knockoff-wegovy-pill-fda-crackdown/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "1002bb24-5eb4-303a-9144-64abe04a7a40",
      "content": {
        "id": "1002bb24-5eb4-303a-9144-64abe04a7a40",
        "contentType": "STORY",
        "title": "Hims & Hers Halts Knockoff Wegovy Pill After Just Two Days: Here's Why",
        "description": "",
        "summary": "Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill.",
        "pubDate": "2026-02-09T11:36:51Z",
        "displayTime": "2026-02-09T11:36:51Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1002bb24-5eb4-303a-9144-64abe04a7a40/hims-hers-halts-knockoff.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/6cfe027a47fbde4d7312dced314aff0b",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3O3uCGa3Xeq_MEs22jdHiA--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/6cfe027a47fbde4d7312dced314aff0b.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pXxP9EU.MV8rjo4qP_AZ6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/6cfe027a47fbde4d7312dced314aff0b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/hims-hers-health-stops-offering-knockoff-wegovy-pill-fda-crackdown/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "VKTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T11:01:26+00:00",
    "headline": "Innovent and Lilly to advance new oncology and immunology medicines",
    "summary": "Innovent will receive an upfront payment of $350m under the agreement.",
    "url": "https://www.pharmaceutical-technology.com/news/innovent-lilly-oncology-immunology-medicines/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "51b5b7c4-3612-3e75-baf4-634022fe74da",
      "content": {
        "id": "51b5b7c4-3612-3e75-baf4-634022fe74da",
        "contentType": "STORY",
        "title": "Innovent and Lilly to advance new oncology and immunology medicines",
        "description": "",
        "summary": "Innovent will receive an upfront payment of $350m under the agreement.",
        "pubDate": "2026-02-09T11:01:26Z",
        "displayTime": "2026-02-09T11:01:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/e614c70ad9a5dd9b5dcfdbfe505debec",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "Lilly will hold exclusive rights to develop and commercialise the programmes outside Greater China. Credit: Tada Images / Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FX.zvlGi.f9_JeOu6nEe8A--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/e614c70ad9a5dd9b5dcfdbfe505debec.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KXKsQ7DfZB7py4t8rztnOQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/e614c70ad9a5dd9b5dcfdbfe505debec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/innovent-lilly-oncology-immunology-medicines/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/innovent-lilly-advance-oncology-immunology-110126837.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IVBIY"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T10:49:22+00:00",
    "headline": "Novo Nordisk surges as Hims pulls $49 weight loss pill under FDA pressure",
    "summary": "COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of a $49 copy of a weight-loss pill following legal threats from the ​Danish group and the U. The gains pushed Novo's shares higher than before Hims announced ‌its non-FDA-approved version of Novo's semaglutide as investors perceived the FDA actions as a broader crackdown on compounded GLP-1 drugs, which could reduce competitive threats ‌to branded treatments,",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "eba1a6c5-1069-3b02-9249-bb65961b531a",
      "content": {
        "id": "eba1a6c5-1069-3b02-9249-bb65961b531a",
        "contentType": "STORY",
        "title": "Novo Nordisk surges as Hims pulls $49 weight loss pill under FDA pressure",
        "description": "",
        "summary": "COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of a $49 copy of a weight-loss pill following legal threats from the ​Danish group and the U. The gains pushed Novo's shares higher than before Hims announced ‌its non-FDA-approved version of Novo's semaglutide as investors perceived the FDA actions as a broader crackdown on compounded GLP-1 drugs, which could reduce competitive threats ‌to branded treatments,",
        "pubDate": "2026-02-09T10:49:22Z",
        "displayTime": "2026-02-09T10:49:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/9cb75f20-05a2-11f1-bf97-4d2d6778d96c",
          "originalWidth": 4448,
          "originalHeight": 2911,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/su9pm8YI6lLwNbzBqOF_Ow--~B/aD0yOTExO3c9NDQ0ODthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/9cb75f20-05a2-11f1-bf97-4d2d6778d96c.cf.webp",
              "width": 4448,
              "height": 2911,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pThKw72ZHlLccJT5LV59Vg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/9cb75f20-05a2-11f1-bf97-4d2d6778d96c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]